Skip to content

OS Therapies OSTX Accrued liabilities

Accrued liabilities at other companies

CTO
Citius Oncology, Inc.CTOR
$19.54M+684%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's accrued liabilities?
OS Therapies (OSTX) reported accrued liabilities of $3.88M in Q1 2026.
How has OS Therapies's accrued liabilities changed year-over-year?
OS Therapies's accrued liabilities increased by 2019.4% year-over-year, from -$202.28K to $3.88M.
What does accrued liabilities mean?
Represents the net change in expenses that have been incurred but not yet invoiced or paid by the end of the reporting period. This metric provides insight into the company's short-term operational obligations and working capital management.